James Investment Research’s Anika Therapeutics ANIK Stock Holding History

James Investment Research’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-48,534	Closed	-$2M	–	504
2015 Q1	$2M	Buy	48,534 +2,510	+5%	+$101K	0.05%	196
2014 Q4	$1.88M	Buy	46,024 +1,054	+2%	+$41.2K	0.05%	193
2014 Q3	$1.65M	Buy	44,970 +2,340	+5%	+$101K	0.05%	193
2014 Q2	$1.98M	Hold	42,630	–	–	0.06%	171
2014 Q1	$1.75M	Buy	42,630 +3,310	+8%	+$123K	0.06%	193
2013 Q4	$1.5M	Buy	39,320 +8,380	+27%	+$259K	0.05%	207
2013 Q3	$739K	Buy	+30,940	New	+$694K	0.03%	240

Other funds holding ANIK

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LCP

Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return

James Investment Research's ANIK Position: Q2 2015 in Review

James Investment Research sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 48,534 shares — an estimated $2M sold.

James Investment Research first reported a position in ANIK in Q3 2013 and held it in 7 quarters. The position peaked at $2M in Q1 2015. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

James Investment Research reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
James Investment Research sold 48,534 Anika Therapeutics shares in Q2 2015, an estimated $2M.
James Investment Research first reported a position in Anika Therapeutics in Q3 2013 and held it in 7 quarters.
James Investment Research's Anika Therapeutics position peaked at $2M in Q1 2015.
136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on James Investment Research's 13F filing for Q2 2015, filed 17 Jul 2015.